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Traditional Chinese medicine (TCM) has been used in clinical
practice for thousands of years and plays an indispensable role in
prevention and treatment of diseases, especially the complicated
and chronic ones. Pharmacokinetic studies on the effective
components of TCM are important to illustrate their distribution
and clearance from the body. Salvia miltiorrhiza, one of the oldest
and most versatile Chinese herb drug, is of great importance for
the treatment of cardiovascular and cerebrovascular diseases1. It
had been listed in the Pharmacopoeia of the People's Republic of
China due to its notable pharmacological activities2.
Salvianolic acid D (SalD) is one of the major antioxidants from
S. miltiorrhiza3. Although the cardiac anti-ischemic effects of
salvianolic acid B (SalB) have been widely reported4–6, an
experiment based on neural network analysis indicated that SalD
was more potent than SalB against myocardial ischemia induced
by pituitrin7. Moreover, water-soluble extracts of S. miltiorrhiza
(especially SalA, SalB and SalD) exhibited potent inhibitory
effects against HIV-1 integrase and this activity mainly resulted
from the acid component of SalD8–10. SalD was also a promising
compound against endothelin converting enzyme 1 (ECE-1),
supporting its use in cardiovascular and cerebrovascular di-
seases11,12. SalD is also the major component of some TCM
preparations including “Danshen” injection13, “QI-SHEN-YI-QI”
dropping pills14, “SHUANGDAN” granules15, and “Fufang Dan-
shen” tablets16. These preparations have been used for the
treatment of cardiovascular diseases in China for several decades
and lots of pharmacological effects have been reported17–22. It is of
great need to study the pharmacokinetics of SalD. Pharmacokinetic
parameters, such as maximum plasma concentration, time to
maximum plasma concentration, area under the concentration-time
curve, volumes of distribution and clearance, are quite useful for
assessing the margins of safety of the drug in clinical use.
To the best of our knowledge, several methods have been reported
for the determination of SalD including HPLC-UV and LC-MS
methods13,23. However, no reports have addressed the pharmaco-
kinetic proﬁle of SalD yet. In the present study, we developed a
sensitive and reliable HPLC–ESI-MS for the quantiﬁcation of
SalD in rat plasma after oral and intravenous administration.
Furthermore, the pharmacokinetic patterns and bioavailability
were also investigated.2. Materials and methods
2.1. Chemicals and reagents
SalD (98% of purity) (Fig. 1) was provided by Institute of Materia
Medica (Beijing, China). Naringin (internal standard (IS), 99% of
purity) (Fig. 1) was purchased from the National Institutes for
Food and Drug Control (Beijing, China). Methanol and acetonitrile(LC-MS grade, J.T. Baker) were purchased from Avantor Perfor-
mance Materials (USA). Formic acid was obtained from TEDIA
(Fairﬁeld, USA). Ultrapure water was prepared by a Milli-Q
Reagent water system (Millipore, USA).2.2. Chromatography and mass spectrometry conditions
Chromatography was carried out on an Agilent 1200 HPLC
system (Agilent, CA, USA). The analyte and IS were chromato-
graphed by injection of 20 μL sample onto a Zorbax SB-C18
column (3.5 μm, 2.1 mm 100 mm, Agilent, USA). The mobile
phase consisted of solvent A (acetonitrile with 0.05% formic acid)
and solvent B (water with 0.05% formic acid). A gradient elution
program was applied as follow: at the initiation time, the solvent
A was set at 5% (v/v) then gradually increased to 30% at 12 min.
Then the solvent A was decreased to 5% suddenly, and the system
was then equilibrated for 5 min before next injection. The ﬂow rate
was 0.3 mL/min with an operating temperature at 35 1C.
An Agilent 6110 quadrupole mass spectrometer with electrospray
source (ESI) was operated in negative ion mode. The capillary
voltage, nebulizer pressure, drying gas ﬂow rate and drying gas
temperature were 3000 V, 35 psig, 10 L/min and 350 1C, respec-
tively. The quantiﬁcation was performed using single ion monitor-
ing (SIM) method with m/z 417 for SalD and m/z 579 for IS. The
fragmentation voltage of SalD was set to 100 V and IS was set to
190 V. The gain and dwell time were 1.5 and 144 ms for both SalD
and IS.2.3. Preparation of calibration standards and quality control
samples
Stock solutions of SalD and IS were prepared by dissolving the
reference standards in acetonitrile at a precise concentration of
1000 μg/mL. All stock standard solutions were stored at –20 1C.
The stock solution of IS was further diluted with acetonitrile to
1 μg/mL as working solution. The SalD stock solution was diluted
and added into blank plasma to obtain calibration curves with ﬁnal
concentration levels of 3.3, 6.7, 16.6, 33.3, 83.3, 166.7, 333.3,
500.0 and 666.7 ng/mL. The quality control (QC) samples were
similarly prepared at concentrations of 6.7, 166.7 and 500.0 ng/mL
Junke Song et al.248for the low, medium and high concentration QC samples. All
working solutions were stored at –20 1C.
2.4. Plasma sample preparation
For the preparation of 150 μL plasma sample, 15 μL IS solution
(1 μg/mL), 10 μL HCl (3 mmol/L), 10 μL vitamin C (10 mg/mL)
and 1 mL ethyl acetate were added to it in an Eppendorf tube.
After vortex-mixing for 5 min, the sample was centrifuged at
13,400 rpm for 10 min. After carefully separation of the sample,
another 1 mL ethyl acetate was added to the same tube for the
second extraction. All the supernatant was carefully transferred to
a new tube and evaporated under a nitrogen atmosphere at 40 1C.
The residue was reconstituted in 75 μL of acetonitrile-H2O (20:80,
v/v). After centrifugation at 13,400 rpm for 10 min, 20 μL of
aliquot was injected into the HPLC-MS system for measurement.
2.5. Method validation
The validation process was carried out according to Guidance for
Industry-Bioanalytical Method Validation (U.S. Food and Drug
Administration, 2013). The validation aspects accessed consisted
of speciﬁcity, carryover, sensitivity, linearity, accuracy, precision,
recovery, matrix effect, stability, dilution effect and incurred
sample reanalysis.
2.5.1. Speciﬁcity
Selectivity was investigated by comparison of the chromatograms
of six different blank plasmas obtained from six rats with the
corresponding spiked samples and plasma samples after single
intravenous administration of SalD.
2.5.2. Carryover
Carryover was evaluated by three injections of an upper limit of
quantiﬁcation (ULOQ) sample, immediately followed by three
injections of a blank plasma sample. It was considered acceptable
if the mean peak area of SalD or IS was no more than 20% for
SalD and 5% for IS, compared to the mean area in the lower limit
of quantiﬁcation (LLOQ) sample.
2.5.3. Linearity of calibration curves and LLOQ
Linearity was investigated over the concentration range of 3.3–
666.7 ng/mL. Six calibration curves of SalD were performed with
nine concentrations. The calibration curves were constructed by
plotting the peak area ratio (Y) of SalD to IS against the nominal
concentration (X). The correlation coefﬁcients were calculated by
weighted least-square regression (1/X2). The LLOQ samples were
prepared with six different batches of blank plasma at the lowest
point of calibration curve with an acceptable accuracy within
720% and the precision below 20%.
2.5.4. Accuracy and precision
Five replicates of QC samples at three concentration levels (6.7,
166.7 and 500.0 ng/mL) on the same day were analyzed to
determine the intra-day precision and accuracy, and the inter-day
precision and accuracy were estimated by determining the QC
samples over ﬁve consecutive days. Relative standard deviation
(R.S.D.%) and relative error (R.E.%) were used to express the
precision and accuracy, respectively. The intra-day and inter-day
precision should not exceed 20% for the low QC samples and 15%for the other QC samples and accuracy should be within 720%
for the low QC samples and 715% for the other QC samples.
2.5.5. Extraction recovery and matrix effect
Extraction recovery of SalD was determined by comparing the
peak area of blank plasma spiked with analyte before and after
extraction at three QC levels (6.7, 166.7 and 500.0 ng/mL) (n¼5).
Matrix effects were measured by comparing the peak areas of the
analytes dissolved in the pretreated blank plasma with that of neat
standard solution containing equivalent amounts of the analytes
(n¼5).
2.5.6. Stability
The stability of this method was investigated under the different
circumstances including freeze-thaw cycles (three cycles of freez-
ing at –20 1C and thawing at 20 1C), at room temperature (20 1C
for 12 h), post-preparation procedure (in the autosampler for 12 h)
and long-term sample storage (–20 1C for 30 days).
All the stability experiments were conducted at low, medium
and high QC samples (n¼5) and the obtained results were
compared with the nominal concentration.
2.5.7. Dilution effect
The dilution effect was investigated to ensure that samples
could be diluted with blank rat plasma without affecting the
ﬁnal concentration. SalD spiked rat plasma samples prepared at
20,000 ng/mL were diluted with blank rat plasma with the dilution
factors of 40 in ﬁve replicates and analyzed for three successive
days. Samples were considered stable if assay values were within
the acceptable limits of accuracy (715% R.E.) and precision (15%
R.S.D.).
2.5.8. Incurred sample reanalysis
Six rats were used for the incurred sample reanalysis after 1 mg/kg
intravenous administration of SalD. Blood samples (1 mL) from
these rats were collected into heparinized tubes by retro-orbital
puncture at only three time point, 2 min, 1 h and 12 h. 300 μL
plasma was separated by centrifugation at 5000 rpm for 10 min.
150 μL of the total plasma was used for the original analysis,
another 150 μL was used for repeat analysis. The variability
difference (%) was calculated using the original and repeat results
as described by the following formula: variability (%)¼2
(repeat–original)/(repeatþoriginal) 100. For the acceptance cri-
terion, at least two thirds of the original results and repeat results
should be within 720%.
2.6. Application to pharmacokinetic study
For the pharmacokinetic study, 18 rats were divided into six per
group with half males and half females and given SalD at 0.25, 0.5
and 1 mg/kg via the tail vein. Another six rats were orally given
4 mg/kg SalD by gastric gavage. Blood samples (0.5 mL) were
collected into heparinized tubes by retro-orbital puncture at 0 (pre-
dose), 2, 5, 10, 20, 30 min, 1, 2, 3, 4, 6, 8 and 12 h after
intravenous administration and at 5, 10, 20, 30 and 45 min, 1, 2, 3,
4, 6, 8 and 12 h after oral administration. Plasma was separated by
centrifugation at 5000 rpm for 10 min and stored at –20 1C until
analysis. The pharmacokinetic parameters were calculated using
the DAS 3.0 pharmacokinetic program (Chinese Pharmacology
Society). A two-compartmental model analysis was employed.
Absolute bioavailability was determined from the ratio of AUC0 t
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i.v. administration and expressed as F (%)¼Dosei.v.AUCp.o./
Dosep.o.AUCi.v. 100.Figure 2 Full scan of SalD and IS: (A) SalD and (B) IS.3. Results
3.1. Validation
3.1.1. Speciﬁcity
Fig. 2 shows full scan MS spectra of SalD and IS. The speciﬁcity
of the method was demonstrated by comparing SIM chromato-
grams of a drug-free plasma sample, a spiked plasma sample, and
a plasma sample from rats at 1 h after intravenous administration.
As shown in Fig. 3, no signiﬁcant peaks interfering with analytes
were observed in the drug-free rat plasma. The retention times for
SalD and IS were approximately 12.7 and 13.0 min, respectively.
These observations indicate that no endogenous substances
signiﬁcantly inﬂuenced the ionization of these analytes.
3.1.2. Carryover
No peak was observed at the retention times of SalD or IS in the
chromatogram of a blank sample analyzed after the injection of
ULOQ sample, indicating the absence of carryover.
3.1.3. Linearity and LLOQ
The validation concentration range was from 3.3 to 666.7 ng/mL
(Y¼0.0065Xþ0.0051, R2¼0.9995, n¼6). The lowest SalD plasma
level on the calibration curves 3.3 ng/mL was recognized as LLOQ.
The accuracy and precision data for LLOQ determination were
9.43% and 12.83% which were both within the acceptable
criteria.
3.1.4. Precision and accuracy
The intra-day, inter-day precision and accuracy of SalD are
summarized in Table 1. The accuracies for all tested concentra-
tions were within 79% of nominal and both the within- and
between-run precisions were acceptable. All the results of the
tested samples were within the acceptable criteria (R.S.D.%: 15%;
R.E.%:715%).
3.1.5. Extraction recovery and matrix effect
The average extraction recoveries at three QC levels were 90.20%
711.57%, 84.04%72.69%, 88.70%72.92% for low, middle and
high QC samples, respectively. The data indicated that extraction
recovery was consistent and reproducible. The matrix effect values
were 95.12%77.73%, 94.07%72.19% and 87.25%75.01% for
SalD at the three QC concentration levels, respectively (Table 2).
3.1.6. Stability
Several stability experiments were performed and the results are
summarized in Table 3. No signiﬁcant changes of SalD concen-
trations were measured after three freeze-thaw cycles (storage at
–20 1C for 30 days, storage for 12 h at room temperature, and 12 h
in the autosampler after preparation). These results indicate that
the compound was stable during storage and sample preparation.
3.1.7. Dilution effect
The dilution effect was conﬁrmed for QC samples that exceeded the
ULOQ. SalD-spiked rat plasma samples prepared at 20,000 ng/mL
were diluted with blank rat plasma at a dilution factor of40 in ﬁve replicates for three successive days. The results showed
that the diluted samples were within the acceptance range (R.S.D.%:
7.38%; R.E.%: –5.78%).
3.1.8. Incurred sample reanalysis
For the incurred-sample reanalysis, 3 time points from 6 rats were
used. Variability of SalD content in all reanalyzed samples was
from –15.86% to 13.56%, suggesting good reproducibility of this
validated method.
3.2. Pharmacokinetic study of SalD
The described method was applied to quantify SalD in rat plasma
following a p.o. 4 mg/kg dose and i.v. 0.25, 0.5, 1 mg/kg doses.
The concentration-time proﬁles are shown in Fig. 4. The main
pharmacokinetic parameters of SalD after i.v. and p.o. adminis-
tration were calculated by a two-compartmental model analysis
(Table 4). The AUC was calculated by the linear trapezoidal
method. The main pharmacokinetic parameters, including area
under concentration-time curve (AUC0 t and AUC01), distribu-
tion half-life (t1/2α), elimination half-life (t1/2β), apparent central
volume of distribution (V1), clearance (CL), elimination rate
constant (K10), transfer rate constants (K12 and K21), ﬁrst-order
absorption rate constant (Ka), and absorption half-life (t1/2Ka)
were determined according to standard equations24. Following the
4 mg/kg p.o. administration, the Cmax was 333.08761.21 ng/mL, and
the Tmax was 1.13370.689 h. SalD showed low bioavailability in rats
with the absolute bioavailability 4.159%70.517%.
Dose proportionality was assessed using the power model in
a manner analogous to the method of Smith et al.25 (P¼α
Doseβ12lnP¼β0þβ1lnDose, in which P is the pharmacokinetic
Figure 3 Typical chromatograms of SalD and IS (A) blank rat plasma; (B) blank rat plasma spiked with SalD and IS; and (C) rat plasma sample
at 1 h after intravenous injection of SalD spiked with IS.
Table 1 Intra-day and inter-day accuracy and precision in rat plasma (n¼5).
Item Nominal conc. (ng/mL) Observed conc. (mean7SD, ng/mL) Accuracy R.E. (%) Precision R.S.D. (%)
Intra-day 6.7 6.8970.53 3.23 7.69
166.7 157.9975.24 5.21 3.32
500.0 455.20716.57 8.96 3.64
Inter-day 6.7 6.4770.33 2.97 5.08
166.7 161.3173.64 3.22 2.26
500.0 474.28724.34 5.14 5.13
Junke Song et al.250variable, α is the typical value of the variable, and β1 is the effect
of dose as a covariate). An ideal proportional model corresponds to
β1¼1 (e.g., P¼αDose), indicating exact dose proportionality.
Deviations of β1 from 1 correspond to deviations from ideal dose
proportionality. Dose proportionality is claimed when the estimate
of the 90% conﬁdence interval (CI) for β1 falls between the
equivalent limits (L, U) proposed by Smith et al.25, where L and U
can be derived according to equations L¼1þlnθL/lnr and
U¼1þlnθH/lnr, respectively. In these equations, θL is the lower
limit of the range, θH is upper limit of the range, and r is the ratio
between the highest and lowest tested doses. The ranges
0.8θL1.25θH and 0.7θL1.43θH were used as the criteria for
dose independence of AUC and C2min over the entire range of
doses administered in this study, respectively. As a result, the
corresponding 90% CI for C2min fell into the acceptance interval,
and the corresponding 90% CI for AUC0–t and AUC0–1 was
slightly outside the acceptance interval (Fig. 5 and Table 5). β1
was 0.90, 0.86 and 0.92 for AUC0–t, AUC0–1 and C2min,
respectively. These results indicated that SalD showed relatively
good dose proportionality for C2min, AUC0–t and AUC0–1, but
more studies are needed for detailed information.4. Discussion and conclusions
Up to now, several papers reporting analytical methods for SalD
determination have used HPLC13,26. However, the HPLC method
requires a relative long running time with a low sensitivity. SalD
was also detected by LC-MS methods, but these methods were
mainly developed for determination of the chemical ﬁngerprint of
TCM drug preparations, which also takes a relatively long running
time and has no method validation13,23,26. No validated method
has been reported for use with the plasma of rat, dog and human
yet. Our single quadrupole mass spectrometry (LC-MS) has a high
sensitivity, a good resolution, a moderate price and is quite
suitable for the pharmacokinetic study of SalD.
Our method was validated by the fact that the calibration curve
for SalD was linear over the range 3.3–666.7 ng/mL with a
coefﬁcient of correlation 40.999. The inter-day and intra-day
precision of analysis was o8%, and the assay accuracy ranged
from 91.04% to 103.23%. The present optimized method was
validated to guarantee reliable determination results for SalD and
was successfully applied to the pharmacokinetic study after both
p.o. and i.v. administration in rat.
Table 2 Recovery and matrix effect in rat plasma (n¼5).
Analyte Nominal conc. (ng/mL) Recovery Matrix effect
Mean7SD (%) R.S.D. (%) Mean7SD (%) R.S.D. (%)
SalD 6.7 90.20711.57 12.83 95.1277.73 8.13
166.7 84.0472.69 3.20 94.0772.19 2.32
IS 500.0 88.7072.92 3.29 87.2575.01 5.74
100.0 95.2273.94 4.14 97.8973.59 3.67
Table 3 Stability of SalD in rat plasma (n¼5).
Condition Nominal conc. (ng/mL) Observed conc. (mean7SD, ng/mL) R.E. (%) R.S.D. (%)
12 h in the autosampler 6.7 6.5570.66 1.75 10.00
166.7 164.78716.79 1.13 10.19
500.0 483.72740.12 3.26 8.29
Three freeze-thaw cycles 6.7 6.7270.62 0.81 9.22
166.7 161.76713.42 2.95 8.30
500.0 493.76746.13 1.25 9.34
12 h at room temperature 6.7 6.4070.48 4.06 7.49
166.7 156.3377.35 6.21 4.70
500.0 467.88739.91 6.42 8.53
20 1C for 30 days 6.7 6.8870.70 3.21 10.21
166.7 160.56716.40 3.67 10.22
500.0 483.16731.40 3.37 6.50
Figure 4 Mean plasma concentration-time curves of SalD. (A) Mean plasma concentration-time curves of rats (i.v., n¼6); (B) semi-logarithmic
axis mean plasma concentration-time curves of rats (i.v., n¼6); (C) mean plasma concentration-time curves of rats with 4 mg/kg dose (p.o., n¼6).
Pharmacokinetic study of salvianolic acid D in rats 251A low Cmax of 333.08761.21 μg/L and very small AUC0 t
value of 8201.74074711.961 μg/L  h were found after 4 mg/kg
oral administration in rats. The bioavailability of SalD was
calculated to be about 4.159%70.517%. Since the structure of
SalD is similar to the structures of SalA and SalB, these phenolic
compounds may have similar pharmacokinetic patterns. Although
there was no previous pharmacokinetic study on SalD, we can get
some guidance from the studies of SalA and SalB pharmacoki-
netics. The bioavailability of SalA was reported and calculated to
be 1.42% in beagle dogs27, and the bioavailability of SalB was
calculated to be about 2.3% in freely moving rats28. These results
indicated that salvianolic acids (including SalA, SalB, SalC and
SalD, etc.) may all have extremely low bioavailability. It was
reported that more than 60% of dosed SalB remained in the
gastrointestinal tract even 4 h after oral administration, indicating
the poor absorption of SalB in rat small intestine29. The lowbioavailability of SalD may also be due to its poor absorption in
rat small intestine. For the further study of SalD, an intravenous
injection method is preferred. In our study, SalD showed relatively
good dose proportionality by i.v. administration of 0.251 mg/kg.
Since SalD is a polyphenol compound with highly potent anti-
oxidation activity, a high dose of SalD could affect the body's
redox and metabolic systems, which could affect the elimination of
SalD and lead to a poor dose proportionality. The dose propor-
tionality of SalB in beagle dogs has been reported30. A linear
relationship of SalB concentrations was observed between AUC
and doses after i.v. 3, 6 and 12 mg/kg, but the clearance and
volume of distribution values obtained at 12 mg/kg were lower
than those at the lower dose, suggesting that a saturated distribu-
tion and metabolism might occur at the high dose of SalB. This
proﬁle of SalB will be an important clue for dose proportionality
investigation of SalD.
Table 4 Compartmental pharmacokinetic parameters of SalD in rat plasma (n¼6).
Parameter Unit i.v. p.o.
0.25 mg/kg 0.5 mg/kg 1 mg/kg 4 mg/kg
t1/2α h 0.06370.049 0.06770.072 0.07970.068 1.46471.459
t1/2β h 1.51471.252 0.96970.547 1.40570.934 17.306743.768
V1 (i.v.) or V1/F (p.o.) L/kg 0.02870.016 0.02370.025 0.02770.023 7.62773.549
CL (i.v.) or CL/F (p.o.) L/h/kg 0.02570.020 0.03170.024 0.03070.022 0.81070.809
AUC(0 t) μg/L  h 14,384.37978443.184 22,813.369711,860.823 46,406.122727,592.645 8201.74074711.961
AUC(01) μg/L  h 14,790.76478572.595 23,269.485711,926.715 47,441.218727,763.107 8321.97774732.386
R_AUC(t/1) % 96.88372.058 97.41771.821 96.95072.552 97.85071.895
K10 1/h 6.951715.027 25.241740.132 24.793737.427 0.12370.103
K12 1/h 30.765755.694 58.500761.077 43.829761.132 0.55070.546
K21 1/h 3.50272.035 2.20571.013 1.94570.735 0.61070.659
Ka 1/h – – – 3.55072.798
t1/2Ka h – – – 0.31970.230
F % – – – 4.15970.517
Figure 5 Relationship between lnPK and lnDose. The dashed lines are the 90% conﬁdence intervals. (A) AUC0 t; (B) AUC01; and
(C) C2min.
Table 5 Assessment of dose proportionality of SalD based
on power model.
Parameter Acceptance
range
β1 90%
Conﬁdence
interval
AUC0–t 0.841.16 0.90 0.741.05
AUC0–1 0.841.16 0.86 0.691.04
C2min 0.741.26 0.92 0.771.06
Junke Song et al.252Because SalD is the major component of more than 20
commercial drug preparations being sold in China, the bioavaila-
bility and dose proportionality studies of SalD could beneﬁt the
clinical use of these preparations. With the results, the concentr-
ation of SalD in patients could be easily estimated and the analysis
method in human plasma could be further developed based on this
method.Acknowledgments
This work was supported by grants from The Key Project for
Drug Innovation (No. 2009ZX09102-123), National Natural Science
Foundation of China (No. 81102492) and Major Scientiﬁc and
Technological Special Project for “Signiﬁcant New Drugs Creation”
(Nos. 2012ZX09301002001001 and 2013ZX09508104001002).References
1. Li MH, Li QQ, Zhang CH, Zhang N, Cui ZH, Huang LQ, et al. An
ethnopharmacological investigation of medicinal Salvia plants (Lamia-
ceae) in China. Acta Pharm Sin B 2013;3:273–80.
2. Chinese Pharmacopoeia Commission. Pharmacopoeia of the People's
Republic of China. 2010 ed. Beijing: China Medical Science Press; 2010.
3. Ai CB, Li LN. Salvianolic acids D and E: two new depsides from
Salvia miltiorrhiza. Planta Med 1992;58:197–9.
4. Pan CS, Lou LX, Huo YQ, Singh G, Chen M, Zhang DM, et al.
Salvianolic acid B and Tanshinone IIA attenuate myocardial ischemia
injury in mice by NO production through multiple pathways. Ther Adv
Cardiovasc Dis 2011;5:99–111.
5. Xue L, Wu Z, Ji XP, Gao XQ, Guo YH. Effect and mechanism of
salvianolic acid B on the myocardial ischemia–reperfusion injury in
rats. Asian Pac J Trop Med 2014;7:280–4.
6. He HB, Shi MQ, Zeng XW, Yang J, Li YK, Wu LM, et al.
Cardioprotective effect of salvianolic acid B on large myocardial
infarction mediated by reversing upregulation of leptin, endothelin
pathways, and abnormal expression of SERCA2a, phospholamban in
rats. J Ethnopharmacol 2008;118:35–45.
7. Yin YQ, Zhu JF, Shen ZB, Tang CP, Yang CY, Sun Y. Neural network
analysis on spectra-effects correlation of anti-ischemic active ingredients in
Xiangdan injection. Chin Tradit Herb Drugs 2009;40:1284–7.
8. Queffélec C, Bailly F, Mbemba G, Mouscadet JF, Hayes S, Debyser Z,
et al. Synthesis and antiviral properties of some polyphenols related to
Salvia genus. Bioorg Med Chem Lett 2008;18:4736–40.
9. Yu S, Zhao G. Development of polyphenols as HIV-1 integrase inhibitors:
a summary and perspective. Curr Med Chem 2012;19:5536–61.
Pharmacokinetic study of salvianolic acid D in rats 25310. Wang XH, Morris-Natschke SL, Lee KH. New developments in the
chemistry and biology of the bioactive constituents of tanshen. Med
Res Rev 2007;27:133–48.
11. Chen SJ, Cui MC, Chen HJ. Virtual screening of active components
from Salviae miltiorrhizae radix et rhizoma for endothelin converting
enzyme. Chin J Exp Tradit Med Form 2014;20:48–51.
12. Wang X, Xiang YH, Ren ZZ, Zhang YL, Qiao YJ. Rational questing
for inhibitors of endothelin converting enzyme-1 from Salvia miltior-
rhiza by combining ligand- and structure-based virtual screening. Can
J Chem 2013;91:448–56.
13. Zhang JL, Cui M, He Y, Yu HL, Guo DA. Chemical ﬁngerprint and
metabolic ﬁngerprint analysis of Danshen injection by HPLC-UV and
HPLC-MS methods. J Pharm Biomed Anal 2005;36:1029–35.
14. Li YF, Qu HB, Cheng YY. Identiﬁcation of major constituents in the
traditional Chinese medicine QI-SHEN-YI-QI dropping pill by high-
performance liquid chromatography coupled with diode array detection-
electrospray ionization tandem mass spectrometry. J Pharm Biomed Anal
2008;47:407–12.
15. He Q, Hu XJ, Cheng YY. Analysis of ‘SHUANGDAN’ granules by
high-performance liquid chromatography–diode array detection–
electrospray ionization tandem mass spectrometry. J Pharm Biomed
Anal 2006;41:485–92.
16. Lv YH, Zhang X, Liang X, Liu XR, Dai WX, Yan SK, et al.
Characterization of the constituents in rat biological ﬂuids after oral
administration of Fufang Danshen tablets by ultra-performance liquid
chromatography/quadrupole time-of-ﬂight mass spectrometry. J
Pharm Biomed Anal 2010;52:155–9.
17. Han JY, Horie Y, Miura S, Akiba Y, Guo J, Li D, et al. Compound
Danshen injection improves endotoxin-induced microcirculatory dis-
turbance in rat mesentery. World J Gastroenterol 2007;13:3581–91.
18. Zhang L, Wang Y, Yu LY, Liu L, Qu HB, Wang Y, et al. QI-SHEN-
YI-QI accelerates angiogenesis after myocardial infarction in rats. Int J
Cardiol 2010;143:105–9.
19. Shang H, Zhang J, Yao C, Liu B, Gao X, Ren M, et al. Qi-shen-yi-qi
dripping pills for the secondary prevention of myocardial infarction: a
randomised clinical trial. Evid Based Complement Alternat Med
2013;2013:738391.
20. Li C, Wang Y, Qiu Q, Shi T, Wu Y, Han J, et al. Qishenyiqi protects
ligation-induced left ventricular remodeling by attenuating inﬂammationand ﬁbrosis via STAT3 and NF-κB signaling pathway. PLoS One 2014;9:
e104255.
21. Yang TY, Wei JC, Lee MY, Chen CM, Ueng KC. A randomized,
double-blind, placebo-controlled study to evaluate the efﬁcacy and
tolerability of Fufang Danshen (Salvia miltiorrhiza) as add-on anti-
hypertensive therapy in Taiwanese patients with uncontrolled hyper-
tension. Phytother Res 2012;26:291–8.
22. Qin RA, Lin J, Li CY, Fu WJ, Huang CY, Yu XM, et al. Study of the
protective mechanisms of Compound Danshen Tablet (Fufang
Danshen Pian) against myocardial ischemia/reperfusion injury via the
Akt-eNOS signaling pathway in rats. J Ethnopharmacol 2014;156:
190–8.
23. Hu P, Liang QL, Luo GA, Zhao ZZ, Jiang ZH. Multi-component
HPLC ﬁngerprinting of Radix Salviae Miltiorrhizae and its LC-MS-
MS identiﬁcation. Chem Pharm Bull 2005;53:677–83.
24. Shargel L, Susanna WP, Yu ABC. Applied biopharmaceutics and
pharmacokinetics. 5rd ed. New York: McGraw-Hill; 2007.
25. Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA,
Callaghan JT, et al. Conﬁdence interval criteria for assessment of dose
proportionality. Pharm Res 2000;17:1278–83.
26. Liu AH, Lin YH, Yang M, Guo H, Guan SH, Sun JH, et al.
Development of the ﬁngerprints for the quality of the roots of Salvia
miltiorrhiza and its related preparations by HPLC-DAD and LC-MSn.
J Chromatogr B Analyt Technol Biomed Life Sci 2007;846:32–41.
27. Sun JL, Zhang L, Song JK, Tian S, Huang C, Feng ZY, et al.
Pharmacokinetic study of salvianolic acid A in beagle dog after oral
administration by a liquid chromatography mass spectrometry method:
a study on bioavailability and dose proportionality. J Ethnopharmacol
2013;148:617–23.
28. Wu YT, Chen YF, Hsieh YJ, Jaw I, Shiao MS, Tsai TH. Bioavaila-
bility of salvianolic acid B in conscious and freely moving rats. Int J
Pharm 2006;326:25–31.
29. Zhang Y, Akao T, Nakamura N, Duan CL, Hattori M, Yang XW, et al.
Extremely low bioavailability of magnesium lithospermate B, an active
component from Salvia miltiorrhiza, in rat. Planta Med 2004;70:
138–42.
30. Li XC, Yu C, Sun WK, Liu GY, Jia JY, Wang YP. Pharmacokinetics
of magnesium lithospermate B after intravenous administration in
beagle dogs. Acta Pharmacol Sin 2004;25:1402–7.
